natgillin/translations-raw huggingface dataset:
Women of childbearing potential should be advised to use appropriate contraception to avoid becoming pregnant during Benepali therapy and for three weeks after discontinuation of therapy.
Ženskam v rodni dobi je treba pojasniti, da morajo med zdravljenjem z zdravilom Benepali in še tri tedne po prenehanju zdravljenja uporabljati ustrezno metodo kontracepcije.
Women of childbearing potential should be advised to use appropriate contraception to avoid becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.
Ženskam v rodni dobi je treba pojasniti, da morajo med zdravljenjem z zdravilom Enbrel in še tri tedne po prenehanju zdravljenja uporabljati ustrezno metodo kontracepcije.
Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant while receiving Bosulif.
Ženskam v rodni dobi je treba svetovati, da med zdravljenjem z zdravilom Bosulif uporabljajo učinkovito kontracepcijo in naj med zdravljenjem ne zanosijo.
Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant while receiving treatment with SUTENT.
Ženskam v rodni dobi moramo svetovati, naj med zdravljenjem z zdravilom SUTENT uporabljajo učinkovito kontracepcijo in naj ne zanosijo.
Women of childbearing potential should be advised to use effective contraception during treatment with Herceptin and for 7 months after treatment has concluded (see section 5.2).
Ženskam v rodni dobi je treba svetovati, naj med zdravljenjem z zdravilom Herceptin ter še 7 mesecev po zaključku zdravljenja uporabljajo učinkovito kontracepcijo (glejte poglavje 5.2).
Women of childbearing potential should be given specialist advice regarding possible effects of Zonegran on the foetus and the risk should be discussed with the patient in relation to the benefits before starting treatment.
Ženske v rodni dobi naj dobijo nasvet specialista o možnih učinkih zdravila Zonegran na plod, pred začetkom zdravljenja pa se je treba z bolnico pogovoriti o njegovih nevarnostih v primerjavi s koristnimi učinki.
Women of childbearing potential should be given specialist advice regarding possible effects of zonisamide on the foetus and the risk should be discussed with the patient in relation to the benefits before starting treatment.
Ženske v rodni dobi naj dobijo nasvet specialista o možnih učinkih zonisamida na plod, pred začetkom zdravljenja pa se je treba z bolnico pogovoriti o njegovih nevarnostih v primerjavi s koristnimi učinki.
Women of childbearing potential should be informed about the risk of teratogenicity;
ženske v rodni dobi je treba seznaniti s tveganjem za teratogenost;
Women of childbearing potential should have adequate birth control and should tell their doctors immediately if they suspect they may be pregnant;
Ženske v rodni dobi morajo uporabljati zadostno kontracepcijo in morajo takoj obvestiti zdravnika, če sumijo, da bi bile lahko noseče;
Women of childbearing potential should not be pregnant or become pregnant while on treatment with Akynzeo.
Ženske v rodni dobi ne smejo biti noseče ali zanositi med zdravljenjem z zdravilom Akynzeo.
Women of childbearing potential should not become pregnant while on Lynparza and not be pregnant at the beginning of treatment.
Ženske v rodni dobi ne smejo biti noseče na začetku zdravljenja z zdravilom Lynparza in ne smejo zanositi med zdravljenjem.
Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 & 4.5).
Ženske v rodni dobi peroralnih kontraceptivov ne smejo uporabljati kot edine metode za nadzor rojstev, ker lahko nevirapin zmanjša koncentracijo teh zdravil v plazmi (glejte poglavji 4.4 in 4.5).
Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 & 4.5).
Ženske v rodni dobi peroralnih kontraceptivov ne smejo uporabljati kot edine metode za nadzor rojstev, ker lahko nevirapin zmanjša njihovo koncentracijo teh zdravil v plazmi (glejte poglavji 4.4 in 4.5).
Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 & 4.5).
Ženske v rodni dobi peroralnih kontraceptivov ne smejo uporabljati kot edine metode za nadzor rojstev, ker lahko nevirapin zmanjša njihovo koncentracijo v plazmi (glejte poglavji 4.4 in 4.5).
Women of childbearing potential should use a reliable contraceptive method to avoid pregnancy whilst being treated with DepoCyte.
Ženske v rodni dobi morajo uporabljati zanesljivo obliko kontracepcije, da preprečijo nosečnost med zdravljenjem z zdravilom DepoCyte.
Women of childbearing potential should use adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last Cimzia administration.
Za preprečevanje nosečnosti morajo ženske v rodni dobi uporabljati, med zdravljenjem in še najmanj 5 mesecev po prekinitvi zdravljenja z zdravilom Cimzia, ustrezno kontracepcijo.
Women of childbearing potential should use adequate contraceptive measures during tolvaptan use.
Ženske v rodni dobi morajo med uporabo tolvaptana uporabljati ustrezne kontracepcijske ukrepe.
Women of childbearing potential should use adequate contraceptive measures during use of this medicine.
Ženske v rodni dobi morajo med uporabo tega zdravila uporabljati ustrezne kontracepcijske ukrepe.
Women of childbearing potential should use an effective contraceptive during treatment with Myocet and up to 6 months following discontinuation of therapy.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z zdravilom Myocet in do 6 mesecev po njem.
Women of childbearing potential should use appropriate contraception when taking tafamidis meglumine and continue to use appropriate contraception for 1-month after stopping treatment with tafamidis meglumine (see section 4.6).
Ženske v rodni dobi morajo med jemanjem tafamidis meglumina uporabljati ustrezno kontracepcijo in z njeno uporabo nadaljevati še 1 mesec po prenehanju zdravljenja s tafamidis megluminom (glejte poglavje 4.6).
Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during Possia therapy.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom Possia za preprečitev nosečnosti uporabljati ustrezno kontracepcijsko zaščito.
Women of childbearing potential should use effective contraception during ONIVYDE treatment and 1 month thereafter.
Ženske v rodni dobi morajo med zdravljenjem in še 1 mesec po zdravljenju z zdravilom ONIVYDE uporabljati učinkovito kontracepcijo.
Women of childbearing potential should use effective contraception during treatment with belatacept and up to 8 weeks after the last dose of treatment since the potential risk to embryonic/foetal development is unknown.
Ženske v rodni dobi morajo med zdravljenjem z belataceptom in še do 8 tednov po prejemu zadnjega odmerka belatacepta uporabljati učinkovito metodo kontracepcije, saj možno tveganje za razvoj zarodka/plodu ni znano.
Women of childbearing potential should use effective contraception during treatment with prucalopride
Ženske v rodni dobi morajo med zdravljenjem s prukalopridom uporabljati učinkovito kontracepcijo.
Women of childbearing potential should use effective contraception during treatment with prucalopride.
Ženske v rodni dobi morajo med zdravljenjem s prukalopridom uporabljati učinkovito kontracepcijo.
Women of childbearing potential should use effective contraception while receiving Perjeta and for 6 months following the last dose of Perjeta.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z zdravilom Perjeta in še 6 mesecev po prejemu zadnjega odmerka zdravila Perjeta.
Women of childbearing potential should use effective contraception while receiving trastuzumab emtansine and for 7 months following the last dose of trastuzumab emtansine.
Ženske v rodni dobi morajo med zdravljenjem s trastuzumabom emtanzinom in še 7 mesecev po zadnjem odmerku trastuzumaba emtanzina uporabljati učinkovito kontracepcijo.
Women of childbearing potential should, use effective contraception during treatment with SCENESSE and for a period of three months thereafter.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom SCENESSE in tri mesece po njem uporabljati učinkovito kontracepcijo.
Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met (see sections 4.4 and 4.6).
nosečnice; ženske v rodni dobi, razen če izpolnjujejo vse pogoje programa za preprečevanje nosečnosti (glejte poglavji 4.4 in 4.6).
Women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see sections 4.4 and 4.6).
Ženske v rodni dobi, razen če izpolnjujejo pogoje programa Thalidomide Celgene za preprečevanje nosečnosti (glejte poglavji 4.4 in 4.6).
women of childbearing potential unless using an effective method of contraception
če ste ženska v rodni dobi in ne uporabljate učinkovite kontracepcijske zaščite
Women of childbearing potential who are not using reliable contraception (see sections 4.4 and 4.6).
Ženske v rodni dobi, ki ne uporabljajo učinkovite kontracepcije (glejte poglavji 4.4 in 4.6).
Women of childbearing potential who do not comply with the Erivedge Pregnancy Prevention Programme (see sections 4.4 and 4.6).
Ženske v rodni dobi, ki ne upoštevajo Programa preprečevanja nosečnosti med uporabo zdravila Erivedge (glejte poglavji 4.4 in 4.6).
Women of childbearing potential who do not comply with the Odomzo Pregnancy Prevention Programme (see sections 4.4 and 4.6).
Ženske v rodni dobi, ki niso vključene v Program preprečevanja nosečnosti pri uporabi zdravila Odomzo (glejte poglavji 4.4 in 4.6).
Women of childbearing potential, unless all the conditions of the pregnancy prevention programme are met (see sections 4.4 and 4.6).
ženske v rodni dobi, če ne izpolnjujejo vseh pogojev programa za preprečevanje nosečnosti (glejte poglavji 4.4 in 4.6),
Women of childbearing potential/ Contraception in females
Ženske v rodni dobi/kontracepcija pri ženskah
Women of childbearing potential/contraception in males and females
Ženske v rodni dobi/kontracepcija pri moških in ženskah
Women of childbearing potential/contraception in males and females
Ženske v rodni dobi/uporaba kontracepcije pri moških in ženskah
Women receiving Myocet should not breastfeed.
Med zdravljenjem z zdravilom Myocet je treba prenehati z dojenjem.
Women should also not become pregnant for one month after stopping treatment.
Poleg tega ženske ne smejo zanositi še en mesec po prekinitvi zdravljenja.
Women should avoid becoming pregnant while taking Gilenya and for two months after treatment has stopped.
Ženske se morajo med zdravljenjem z zdravilom Gilenya in dva meseca po zdravljenju izogibati zanositvi.
Women should be advised that if they feel dizzy, they should not drive or use machines.
Ženskam svetujte, naj v primeru omotičnosti ne vozijo in ne upravljajo s stroji.
Women should be advised what changes in their breasts should be reported to their doctor or nurse (see ‘Breast cancer’ below).
Ženskam je treba svetovati, o katerih spremembah na dojkah morajo poročati zdravniku ali medicinski sestri (glejte »Rak dojke« spodaj).
Women should not become pregnant for 1 month after discontinuation of Opsumit.
Ženske še 1 mesec po prekinitvi uporabe zdravila Opsumit ne smejo zanositi.
Women should not breast-feed during treatment as DepoCyte may enter breast milk.
Ženske med zdravljenjem z zdravilom DepoCyte ne smejo dojiti, kajti zdravilo lahko prehaja v materino mleko.
Women should not breast-feed during treatment with Corbilta.
Med zdravljenjem z zdravilom Corbilta je treba prenehati z dojenjem.
Women should not breast-feed during treatment with Levodopa/Carbidopa/Entacapone Orion.
Med zdravljenjem z zdravilom Levodopa/Carbidopa/Entacapone Orion je treba prenehati z dojenjem.
Women should not breastfeed while treated with ORENCIA and for up to 14 weeks after the last dose of abatacept treatment.
Med zdravljenjem in še do 14 tednov po prejemu zadnjega odmerka abatacepta ženske ne smejo dojiti.
Women should not get pregnant during treatment with Efavirenz Teva and for 12 weeks thereafter.
Ženske med jemanjem in 12 tednov po prenehanju jemanja zdravila Efavirenz Teva ne smejo zanositi.
Women should not get pregnant during treatment with SUSTIVA, and for 12 weeks thereafter.
Ženske med jemanjem in 12 tednov po prenehanju jemanja zdravila SUSTIVA ne smejo zanositi.
Women should tell their doctor immediately if they suspect that they might be pregnant.
Ženske se morajo takoj posvetovati s svojim zdravnikom, če menijo, da bi bile lahko noseče.
Women should use effective contraceptives during treatment with Ilaris and for up to 3 months after the last dose.
Ženske morajo med zdravljenjem z zdravilom Ilaris in do 3 mesece po zadnjem odmerku uporabljati učinkovita kontracepcijska sredstva.
Women taking DUAVIVE should not be taking progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs).
Ženske, ki jemljejo zdravilo DUAVIVE, ne smejo jemati progestinov, dodatnih estrogenov ali selektivnih modulatorjev estrogenskih receptorjev (SERM – selective oestrogen receptor modulators).
Women taking DUAVIVE should not take additional oestrogens as this may increase the risk of endometrial hyperplasia and endometrial carcinoma.
Ženske, ki jemljejo zdravilo DUAVIVE, ne smejo jemati dodatnih estrogenov, saj to lahko zveča tveganje za hiperplazijo endometrija in karcinom endometrija.
Women taking Marixino should not breast-feed.
Ženske, ki jemljejo zdravilo Marixino, ne smejo dojiti.
Women taking Memantine Mylan should not breast-feed.
Ženske, ki jemljejo zdravilo Memantin Mylan, ne smejo dojiti.
Women taking Nemdatine should not breast-feed.
Ženske, ki jemljejo zdravilo Nemdatine, ne smejo dojiti.
Women taking Tyverb with capecitabine survived for an average of 75 weeks, and those taking capecitabine alone survived for an average of 64.7 weeks.
Ženske, ki so jemale zdravilo Tyverb v kombinaciji s kapecitabinom, so v povprečju preživele 75 tednov, tiste, ki so jemale le kapecitabin, pa so v povprečju preživele 64,7 tedna.
Women that can become pregnant should use birth control while taking Vyndaqel and should continue using birth control for one month after stopping treatment with Vyndaqel.
Ženske, ki bi lahko zanosile, morajo v obdobju jemanja zdravila Vyndaqel uporabljati ustrezno kontracepcijo in morajo z uporabo le-te nadaljevati še en mesec po prenehanju zdravljenja z zdravilom Vyndaqel.
Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive technologies
Ženske v postopku stimulacije ovarijev za doseganje razvoja več foliklov pred oploditvijo in vitro ali drugimi postopki asistirane reprodukcije
Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF):
Ženske, v postopku sprožitve superovulacije pred postopki asistirane reprodukcije, kot je npr. oploditev in vitro (IVF):
Women using Intrinsa should also use oestrogens, but not of the type known as ‘conjugated oestrogens’ because the combination of these with Intrinsa is not as effective as the combination of other types of oestrogen with Intrinsa.
Ženske, ki uporabljajo zdravilo Intrinsa, morajo prejemati tudi estrogen, vendar ne vrste estrogena, ki se imenuje „konjugirani estrogen“, ker ta v kombinaciji z zdravilom Intrinsa ni tako učinkovit kot druge vrste estrogena v kombinaciji z zdravilom Intrinsa.
Women using IOA
Ženske, ki uporabljajo zdravilo IOA
Women using Livensa should also use oestrogens, but not of the type known as ‘conjugated oestrogens’ because the combination of these with Livensa is not as effective as the combination of other types of oestrogen with Livensa.
Ženske, ki uporabljajo zdravilo Livensa, morajo prejemati tudi estrogen, vendar ne vrste estrogena, ki se imenuje „konjugirani estrogen“, ker ta v kombinaciji z zdravilom Livensa ni tako učinkovit kot druge vrste estrogena v kombinaciji z zdravilom Livensa.
Women using these types of hormonal contraceptives must also use a second ‘barrier’ method (such as condoms or diaphragm with spermicide).
Ženske, ki uporabljajo te vrste hormonskih kontraceptivov, morajo uporabljati dodatno "pregradno" metodo (kot so kondomi ali diafragma s spermicidom).
Women vaccinated with Gardasil at 16-23 years of age in Protocol 015 base study will be followed up to 14 years in an extension study.
Ženske, cepljene s cepivom Gardasil v starosti od 16 do 23 let v izhodiščni študiji po protokolu 015, bodo v podaljšanju študije spremljali do 14 let.
Women vaccinated with Gardasil at 24-45 years of age in Protocol 019 base study will be followed up to 10 years in an extension study.
Ženske, cepljene s cepivom Gardasil v starosti od 24 do 45 let v izhodiščni študiji po protokolu 019, bodo v podaljšanju študije spremljali do 10 let.
Women vaccinated with Silgard at 24-45 years of age in Protocol 019 base study will be followed up to 10 years in an extension study.
Ženske, cepljene s cepivom Silgard v starosti od 24 do 45 let v izhodiščni študiji po protokolu 019, bodo v podaljšanju študije spremljali do 10 let.
Women weighing less than 50 kg or more than 90 kg
Ženske z telesno maso manj kot 50 kg ali več kot 90 kg
Women who are able to conceive should use effective contraceptive methods during each treatment course with LEMTRADA and for 4 months after each course of treatment.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med vsakim postopkom zdravljenja z zdravilom LEMTRADA in še štiri mesece po vsakem postopku zdravljenja.
Women who are able to get pregnant should use effective contraception during treatment and up to 5 months after treatment.
Ženske, ki lahko zanosijo, morajo med zdravljenjem in do 5 mesecev po zdravljenju uporabljati učinkovito kontracepcijo.
women who are anovulatory (do not produce eggs) and do not respond to treatment with clomiphene citrate (another medicine that stimulates ovulation). women who are undergoing fertility treatment (assisted reproductive techniques, such as in vitro fertilisation).
pri ženskah z anovulacijo (ki ne proizvajajo jajčec) in ženskah, ki se niso odzvale na zdravljenje s klomifen citratom (drugim zdravilom, ki spodbuja ovulacijo); pri ženskah, ki se zdravijo zaradi neplodnosti (postopki asistirane reprodukcije, kot je in vitro oploditev).
women who are anovulatory (do not produce eggs) and do not respond to treatment with clomiphene citrate (another medicine that stimulates ovulation); women who are undergoing fertility treatment (assisted reproductive techniques, such as in vitro fertilisation).
pri ženskah z anovulacijo (ki ne proizvajajo jajčec) in ženskah, ki se niso odzvale na zdravljenje s klomifen citratom (drugim zdravilom, ki spodbuja ovulacijo); pri ženskah, ki se zdravijo zaradi neplodnosti (postopki asistirane reprodukcije, kot je oploditev in vitro).
Women who are breast-feeding (see section 4.6).
Ženske, ki dojijo (glejte poglavje 4.6).
Women who are breast-feeding during Neulasta treatment are encouraged to enrol in Amgen’s Lactation Surveillance programme.
Ženskam, ki med zdravljenjem z zdravilom Neulasta dojijo, je treba priporočiti vključitev v program družbe Amgen za spremljanje izpostavljenosti zdravilu med dojenjem.
Women who are breast-feeding during Prolia treatment are encouraged to enrol in Amgen’s lactation surveillance program.
Ženskam, ki med zdravljenjem z zdravilom Prolia dojijo, priporočamo vključitev v program družbe Amgen za spremljanje izpostavitve zdravilu med dojenjem.
Women who are breast-feeding during Ristempa treatment are encouraged to enrol in Amgen’s Lactation Surveillance programme.
Ženskam, ki med zdravljenjem z zdravilom Ristempa dojijo, je treba priporočiti vključitev v program družbe Amgen za spremljanje izpostavljenosti zdravilu med dojenjem.
Women who are HIV-positive must not breast-feed because HIV infection can be passed on to the baby in breast milk.
Ženske, ki so HIV-pozitivne, ne smejo dojiti, saj se okužba z virusom HIV lahko z materinim mlekom prenese na otroka.
Women who are HIV-positive must not breast-feed, because HIV infection can be passed on to the baby in breast milk.
HIV-pozitivne ženske ne smejo dojiti, ker se lahko okužba s HIV z materinim mlekom prenese na otroka.
Women who are HIV-positive must not breast-feed, because HIV infection can be passed on to the baby in breast milk.
Ženske, ki so HIV pozitivne, ne smejo dojiti otrok, kajti okužba z virusom HIV se lahko prenese na otroka z materinim mlekom.
Women who are HIV-positive must not breast-feed, because HIV infection can be passed on to the baby in breast milk.
Ženske, ki so HIV pozitivne, ne smejo dojiti, ker se lahko okužba s HIV z mlekom prenese na otroka.
Women who are not ovulating
Ženske, ki nimajo ovulacije
Women who are nursing during XGEVA treatment are encouraged to enrol in Amgen’s Lactation Surveillance Programme.
Ženskam, ki med zdravljenjem z zdravilom XGEVA dojijo, je treba priporočiti vključitev v program družbe Amgen za spremljanje izpostavitve zdravilu med dojenjem.
Women who are or may be pregnant should not handle ZYTIGA without gloves.
Ženske, ki so ali bi lahko bile noseče, morajo z zdravilom ZYTIGA rokovati z rokavicami.
Women who are or may potentially be pregnant (see section 4.6).
Ženske, ki so noseče oziroma bi lahko bile noseče (glejte poglavje 4.6).
women who are pregnant or breast-feeding
pri ženskah, ki so noseče ali dojijo
Women who are pregnant or breast-feeding (see sections 4.4 and 4.6).
Nosečnice in doječe ženske (glejte poglavji 4.4 in 4.6).
Women who are pregnant or trying to become pregnant should not handle MabCampath.
Ženske, ki so noseče ali načrtujejo nosečnost, ne smejo biti v stiku z zdravilom MabCampath.
Women who are pregnant or who may be pregnant should wear gloves if they need to touch or handle ZYTIGA.
Ženske, ki so ali bi lahko bile noseče, morajo v primeru stika ali rokovanja z zdravilom ZYTIGA nositi zaščitne rokavice.
Women who are pregnant, planning to be or breastfeeding should not handle Xaluprine.
Ženske, ki so noseče, načrtujejo nosečnost ali dojijo, ne smejo ravnati z zdravilom Xaluprine.
women who are pregnant;
nosečnice;
Women who become pregnant after taking ellaOne should contact their doctor (see section 4.6).
Ženske, ki zanosijo po jemanju zdravila ellaOne, se morajo posvetovati z zdravnikom (glejte poglavje 4.6).
Women who become pregnant during Aranesp treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance programme.
Ženskam, ki med zdravljenjem z zdravilom Aranesp zanosijo, priporočamo vključitev v program družbe Amgen za spremljanje nosečnosti.
Women who become pregnant during Neulasta treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme.
Ženskam, ki med zdravljenjem z zdravilom Neulasta zanosijo, priporočamo vključitev v program družbe Amgen za spremljanje nosečnosti.
Women who become pregnant during Prolia treatment are encouraged to enrol in Amgen’s pregnancy surveillance programme.
Ženskam, ki med zdravljenjem z zdravilom Prolia zanosijo, priporočamo vključitev v program družbe Amgen za spremljanje nosečnosti.
Women who become pregnant during Ristempa treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme.
Ženskam, ki med zdravljenjem z zdravilom Ristempa zanosijo, priporočamo vključitev v program družbe Amgen za spremljanje nosečnosti.
Women who become pregnant during XGEVA treatment are encouraged to enrol in Amgen’s Pregnancy Surveillance Programme.
Ženskam, ki med zdravljenjem z zdravilom XGEVA zanosijo, priporočamo vključitev v program družbe Amgen za spremljanje nosečnosti.
women who could become pregnant
pri ženskah, ki utegnejo zanositi